Insane cheap here Lilly has assumed all development and commercialization rights to type 2 diabetes drug candidate TT401. If TT-401 is successfully commercialized, Transition will be eligible to receive approximately US$240 million in additional milestone payments. Transition will also be eligible to receive a double-digit royalty on sales of TT401 products and a low single digit royalty on related compounds.
just 1 of several products TTH working on. Not far off either. If it gets commericaized $240million. Plus royalties. Insane potential